Abstract |
CHOP combined with rituximab (R-CHOP) is regarded as one of the most effective treatments for indolent B-cell non-Hodgkin lymphoma (B-NHL), however, its optimal combination schedule remains unknown. We performed a randomized phase II study to explore a more promising schedule in untreated, advanced indolent B-NHL. Patients were randomized to receive either six courses of CHOP concurrently with rituximab (Arm C), or six courses of CHOP followed by six courses of weekly rituximab (Arm S). A total of 69 patients received the concurrent (n=34) or sequential (n=35) regimen. Overall response rate (ORR) in Arm C was 94% (95% confidence interval [CI], 79 to 99), including a 66% complete response (CR) compared with 97% (95% CI, 85-100), including a 68% CR in Arm S. Patients in Arm C experienced more grade 4 neutropenia (85%versus 70%) and experienced more grade 3 or greater non-hematological toxicities (21%versus 12%). Both arms were tolerated well. With a median follow-up of 28.2 months, the median progression-free survival (PFS) time was 34.2 months in Arm C, and was not reached in Arm S. R-CHOP is highly effective in untreated indolent B-NHL, either concurrent or in a sequential combination. Both combination schedules deserve further investigation.
|
Authors | Michinori Ogura, Yasuo Morishima, Yoshitoyo Kagami, Takashi Watanabe, Kuniaki Itoh, Tadahiko Igarashi, Tomomitsu Hotta, Tomohiro Kinoshita, Yasuo Ohashi, Shigeo Mori, Takashi Terauchi, Kensei Tobinai |
Journal | Cancer science
(Cancer Sci)
Vol. 97
Issue 4
Pg. 305-12
(Apr 2006)
ISSN: 1347-9032 [Print] England |
PMID | 16630123
(Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | (Cancer Sci 2006; 97: 305 - 312). |
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Murine-Derived
- Rituximab
- Vincristine
- Doxorubicin
- Cyclophosphamide
- Prednisolone
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal
(administration & dosage)
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, therapeutic use)
- Cyclophosphamide
(administration & dosage)
- Doxorubicin
(administration & dosage)
- Female
- Humans
- Lymphoma, B-Cell
(drug therapy)
- Lymphoma, Follicular
(drug therapy)
- Lymphoma, Non-Hodgkin
(drug therapy)
- Male
- Middle Aged
- Prednisolone
(administration & dosage)
- Rituximab
- Survival Rate
- Treatment Outcome
- Vincristine
(administration & dosage)
|